Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

513 results about "Reprogramming" patented technology

In biology, reprogramming refers to erasure and remodeling of epigenetic marks, such as DNA methylation, during mammalian development or in cell culture. Such control is also often associated with alternative covalent modifications of histones.

Enhancer RNA molecule MZGAe1 and application thereof

The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1 and application thereof, and relates to the technical field of biology. The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1. The nucleotide sequence of the enhancer RNA molecule MZGAe1 is as shown in SEQ ID NO: 1; meanwhile, the invention further provides a specific sgRNA sequence for activating the molecule in a targeted manner and a recombinant vector of the specific sgRNA sequence. Expression of endogenous MZGAe1 of cells is specifically activated by adopting a CRISPR activation technology, and conversion of mouse embryonic stem cells to bicellular-like cells can be efficiently promoted. By providing a brand-new endogenous targeted MZGAe1 accurate activation tool, the efficient transformation of wild mouse embryonic stem cells to bicellular cells can be realized only under the condition of endogenous activation of single enhancer RNA molecule MZGAe1, the proportion is at least increased by 5%, the expression of a totipotent marker gene ZSCAN4 is activated, and the expression of the totipotent marker gene ZSCAN4 is promoted. And an efficient and specific brand-new research tool and scheme are provided for researching zygote genome activation, embryonic development early events and cell reprogramming.
Owner:NANCHANG UNIV

Compounds that participate in cooperative binding and uses thereof

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiments, the compounds of the invention “re-program” the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein (e.g., do not show detectable binding in mammalian cells absent the compound). In some embodiments, provided compounds “re-program” presenter protein binding to greatly enhance interaction with a particular target with which it may have some interaction absent the compound. Interactions achieved through such reprogramming result in an ability to modulate the activity of these new targets.
Owner:REVOLUTION MEDICINES INC

Reprogrammable fanzor polynucleotides and uses thereof

Systems, methods and composition for targeting polynucleotides are detailed herein. In particular, engineered DNA-targeting systems comprising novel Fanzor polypeptides and a reprogrammable targeting nucleic acid component and methods and application of use are described.
Owner:THE BROAD INST INC +1

Collagen biosynthesis method based on induced pluripotent stem cell technology

The invention belongs to the technical field of protoprotein biosynthesis, and particularly relates to a collagen biosynthesis method based on an induced pluripotent stem cell technology, and the collagen biosynthesis method specifically comprises the following steps: step 1, cell reprogramming: extracting somatic cells including fibroblasts and blood cells from the skin or blood of a donor, reprogramming factors are introduced into somatic cells by using a viral vector or a non-viral method, wherein the viral vector is a retrovirus or an adeno-associated virus. The method can utilize donor cells to synthesize collagen, avoids immunological rejection, realizes personalized medical treatment, reduces ethical dispute, optimizes culture and gene regulation to improve synthesis efficiency and quality, ensures genetic stability and pluripotency through strict quality control, can test and evaluate biological activity and mechanical properties, ensures high purity through multiple extraction and purification technologies, and is suitable for industrial production. Quality detection ensures that natural standards are met.
Owner:BEIJING SAIWEISEN INT BIOTECHNOLOGY CO LTD

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Reprogrammed cell modulation of cancer microenvironment by tumor homing personalized regenerative cells

Disclosed are methods of augmenting efficacy of oncology therapies by providing reprogrammed cells such as personalized regenerative cells that modulate the tumor microenvironment. In one embodiment, somatic cells are dedifferentiated into OCT-4 expressing cells and endowed with tumor homing properties through culture or gene engineering. Once a stable population of tumor homing cells is established, such cells are made to express immune stimulating agents constitutively, or selectively upon entering the cancer microenvironment. Selective expression of immune stimulatory agents can be induced by exposure to hypoxia, acidosis, immune suppressive signaling or inflammatory signaling.
Owner:IMMORTA BIO INC

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Application of Smad6 gene in promoting reprogramming of fibroblasts into stem cells

The invention discloses an application of a Smad6 gene in promoting reprogramming of fibroblasts into stem cells. According to the application, Smad2 / 3 activation is inhibited through overexpression of the Smad6 gene, and up-regulation of important transcription factors C-Myc, Nanog and Oct4 in the stem cell state is promoted to be maintained and regulated, so that fibroblasts are promoted to be reprogrammed into the stem cells. According to the method, the roe mother cell extracting solution is adopted as an inducer to induce fibroblasts to be reprogrammed into the stem cells, and the materials are low in cost, wide in source and safe. According to the application disclosed by the invention, by means of overexpression of the Smad6 gene, fibroblasts induced by a fish egg mother cell extracting solution are promoted to be reprogrammed into stem cells, expression of stem cell related genes C-Myc, Nanog and Oct4 is promoted, activation of a TGF-beta signal channel is inhibited, expression of TGF-beta signal channel related genes Smad2, Smad3 and Smad4 is regulated and controlled, and the stem cells are obtained. The efficiency of reprogramming the somatic cells into the stem cells is improved, and the application of reprogramming is greatly promoted.
Owner:920TH HOSPITAL OF THE JOINT LOGISTIC SUPPORT FORCE OF THE CHINESE PEOPLES LIBERATION ARMY

Reversing aging of the central nervous system

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Liver precursor cell and construction method therefor and use thereof

PCT designated stage expiredWO2025039158A1HepatocytesGenetically modified cellsReprogrammingCell strain
Provided are a liver precursor cell and a construction method therefor and the use thereof. The method for constructing liver precursor cells comprises the steps of: S0, providing liver precursor cells, a mixed solution and a reprogramming culture medium, wherein the mixed solution comprises a serum-free culture medium, polyethyleneimine and a CLP plasmid; S1, carrying out a transfection treatment on the liver precursor cells and the mixed solution to obtain transfected liver precursor cells; and S2, placing the transfected liver precursor cells into the reprogramming culture medium for subculture to obtain immortalized liver precursor cells. The method solves the problems that in the prior art, liver precursor cells cannot be transformed into immortalized cell strains by means of immortalizing genes and cannot be continuously passaged in vitro.
Owner:SHANGHAI CELLIVER BIOTECHNOLOGY CO LTD

Cell reprogramming methods

The present invention relates to a method for producing reprogrammed cells from somatic cells without gene introduction. The method comprises: (a) culturing somatic cells in a medium containing a histone deacetylase inhibitor; and (b) culturing the cells cultured in step (a) in a medium containing an OCT3 / 4 transcription stimulating factor to produce reprogrammed cells.
Owner:岛崎猛夫

Cell fast chemical reprogramming technique

PCT designated stage expiredWO2024251268A1AntipyreticAnalgesicsBiotechnologyReprogramming
Provided is a cell fast chemical reprogramming technique. By means of a provided chemical reprogramming accelerator and culture method, the time for chemical reprogramming is significantly shortened, and the reprogramming efficiency is improved by more than 10 times. The provided method can be applied to a wider range of genetic backgrounds and more types of mouse cells.
Owner:ZHEJIANG UNIV

Application of polypeptide for specifically blocking phosphorylation of metabolic enzyme PSAT1 S337 and functional remodeling of PSAT1 in preparation of product for treating triple negative breast cancer

The invention belongs to the technical field of triple negative breast cancer, and particularly relates to application of a polypeptide capable of specifically blocking phosphorylation of metabolic enzyme PSAT1S337 and functional remodeling of PSAT1 in preparation of a triple negative breast cancer treatment product. The phosphorylated polypeptide targeting PSAT1S337 is designed, and it is found that the polypeptide obviously inhibits growth of triple negative breast cancer tumors and can improve the curative effect of anti-PD-1 immunotherapy at the animal level. Meanwhile, the invention further provides application of the reagent for detecting the phosphorylation level of the PSAT1S337 and / or the hydroxylation level of the GPX4P159 in preparation of products for diagnosing and prognosing the triple negative breast cancer. The invention discloses a molecular mechanism of functional remodeling of the serine metabolic enzyme PSAT1 in occurrence and development of cell ferroptosis and triple negative breast cancer, and provides a new thought and an effective scheme for research and development of anti-tumor drugs for targeted serine metabolism reprogramming and early diagnosis of tumors.
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE

Method for inducing fibroblasts to be reprogrammed into osteoblasts

PendingCN119614488AResist stressEnhance and maintain osteogenic differentiationSkeletal disorderSkeletal/connective tissue cellsOsteoblastReprogramming
The invention belongs to the technical field of cell small molecule compound reprogramming and bone tissue engineering material culture, and discloses a method for inducing fibroblasts to be reprogrammed into osteoblasts. According to the invention, small molecule compounds act on fibroblasts, each small molecule is endowed with characteristics of a set of characteristic gene expression mode, and the small molecules are divided into different modules according to the expression characteristic mode, so that the fibroblasts of the cells are converted into osteogenic differentiation, the osteogenic differentiation effect is enhanced and maintained, and the in-vivo development of the cells is simulated to a great extent; therefore, healthy osteoblasts can be prepared from the skin fibroblasts, cell stress pressure can be resisted, and the prepared cells are free of tumorigenicity, safe and healthy. The osteoblast disclosed by the invention can be applied to preparation of bone materials and medicines for treating bone defects, for example, the osteoblast and a traditional bone material are used for constructing an active bone tissue engineering material, so that the use of allogeneic bones commonly used in clinic at present is avoided, and the occurrence of adverse ethical events is reduced.
Owner:YUNNAN JICI INSITUTE FOR REGENERATIVE MEDICINE CO LTD

Preparation method of reprogramming induced pluripotent stem cells of PBMC (peripheral blood mononuclear cells) and kit

The invention provides a preparation method and a kit for reprogramming induced pluripotent stem cells of PBMC (peripheral blood mononuclear cells), particularly provides PBMC reprogramming based on mRNA-LNP (peripheral blood mononuclear cells), and more particularly relates to a preparation method for reprogramming induced pluripotent stem cells of peripheral blood mononuclear cells. The preparation method comprises the following steps: preparing a nano liposome mRNA (messenger ribonucleic acid) cocktail-LNP; according to the method, the nano-liposome mRNA-LNP is used for inducing peripheral blood mononuclear cells to reprogram, so that reprogrammed induced pluripotent stem cells are obtained, and an iPSCs reprogramming technology which is low in cost, low in toxicity, efficient, stable, repeatable and safer is realized. The invention also provides a reprogramming kit and a preparation method of the induced pluripotent stem cells.
Owner:NANJING HONGMING BIOTECHNOLOGY CO LTD +2

Mesenchymal progenitor cells for enhancing partial reprogramming of target cells

Provided herein are methods and related compositions for enhancing or enhanced partial reprogramming of target cells in a subject in need thereof (e.g., a human subject suffering from or at risk of a disease), the method comprising administering a plurality of mesenchymal lineage progenitor or stem cells (MLPSCs), exosomes derived therefrom, or conditioned culture media derived therefrom to a subject that expresses or will express one or more reprogramming factors in a population of target cells, whereby a plurality of the target cells in the subject become partially reprogrammed, but not fully reprogrammed.
Owner:MESOBLAST INTERNATIONAL SARL

Liver regeneration method through liver-specific delivery of dedifferentiation gene

The present invention relates to novel lipid nanoparticles capable of liver-specific delivery of mRNA, a manufacturing method therefor, and a liver disease therapeutic agent capable of regenerating the liver by liver-specific delivery of the bio-reprogramming factor mRNA using same. The lipid nanoparticles according to the present invention allow for liver-specific delivery of mRNA at very high efficiency, and the lipid nanoparticles that encapsulate the mRNA-based bio-reprogramming factor mRNA are specifically delivered to liver tissues of an individual requiring liver regeneration to induce short-term expression, thereby easily setting the dose and expression period of a therapeutic agent, leading to a significant reduction in side effects of a therapeutic agent for liver regeneration using an existing cell reprogramming factor.
Owner:SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION +1

Application of miRNA in regulation and control of cell reprogramming

The invention relates to application of miRNA (micro Ribonucleic Acid) in regulation and control of cell reprogramming. It is found for the first time that a mixture of three miRNAs of hsa-miR-647, hsa-miR-450b-5p and hsa-miR-875-5p can induce fibroblasts to be reprogrammed into induced pluripotent stem cells, the three miRNAs have a synergistic effect, the statistical number of positive iPSCs colonies under combined transfection is obviously increased, and the expression quantity of Oct4, Sox2, c-Myc and Klf4 transcription factors generated through induction is also obviously increased. The reprogramming effect of the mixture of the three miRNAs is further proved, and the mixture can be used for realizing reprogramming of somatic cells. Compared with compound-induced reprogramming, the method disclosed by the invention has the advantages that a large number of induced pluripotent stem cells can be rapidly and efficiently obtained through in-vitro induction, the reediting efficiency is far higher than that of a currently known reediting method in the prior art, and the method has a good commercial application prospect.
Owner:GUANGZHOU ZEUS STEM CELL PEPTIDE NEW MATERIAL TECH CO LTD

Preparation of chemically reprogrammed pericyte-like cells and application of chemically reprogrammed pericyte-like cells in sepsis treatment

The invention discloses a medicine composition for inducing fibroblasts to be reprogrammed into pericyte-like cells (PCLCs) through a chemical small molecule combination, and the medicine composition is used for treating sepsis. According to the invention, a chemical reprogramming strategy without genetic modification is adopted, an endogenous signal channel is activated through a time sequence, and fibroblasts from somatic cells are efficiently converted into PCLCs with high expression of genes such as EMILIN3, LAMC3, GDF10, AHR, CD109, AHR, NQO1, QPRT and the like. When applied to treatment of sepsis, the medicine composition can improve pathological symptoms and reduce death rate by synergistically exerting anti-inflammatory, anti-oxidation, immune regulation and tissue barrier protection effects. The invention provides a novel safe treatment strategy based on non-genetically modified cells for sepsis.
Owner:HONGFANG BIOTECHNOLOGY (ZHENJIANG) CO LTD

Culture medium for inducing hypoderm stem cells and application thereof

The invention relates to a culture medium for inducing hypoderm stem cells and application thereof, and belongs to the technical field of stem cells. The invention provides a culture medium for inducing hypoderm stem cells. The culture medium for inducing the hypoderm stem cells comprises the following components: a platelet-derived growth factor AA (PDGFAA), a leukemia inhibition factor (LIF), a fibroblast growth factor 4 (FGF4), a GSK-3alpha / beta inhibitor CHIR99021, a TGF-beta I type receptor inhibitor A83-01 and a bone forming protein 4 (BMP4). The culture medium for inducing the hypoderm stem cells can accurately regulate and control the activity of key signal channels such as NODAL, BMP, WNT, FGF and JAK / STAT in the somatic cell reprogramming process, and ensures that the somatic cells maintain the characteristics of the hypoderm stem cells in the reprogramming process so as to support self-renewal and hypoderm lineage induction of the somatic cells in the reprogramming process; therefore, the fate transformation from the somatic cells to the hypoderm stem cells is realized.
Owner:NOVAREACH INC

Application of HP and ICT combined anti-PD-1 inhibitor hydrogel in residual cancer recurrence after IRFA

The invention belongs to the technical field of anti-tumor, and discloses application of HP and ICT combined anti-PD-1 inhibitor hydrogel in residual cancer recurrence after IRFA. The excellent drug delivery capacity of the hydrogel system is utilized, and the in-vivo local slow release effect of ICT and BMS202 can be remarkably amplified. Through synergistic treatment of the TAN and the MDSC, local and whole body adaptive immunoreactions can be efficiently activated, TAN is effectively reprogrammed to be in a tumor suppression type, infiltration of PMN-MDSC is reduced, and the conclusion is verified in a plurality of mouse tumor models in the chapter. Therefore, the HP (at) ICT / BMS provides a promising delivery strategy for improving the sensitivity of anti-PD-L1 treatment and efficiently preventing and treating latent residual cancer and metastasis after IRFA operation.
Owner:THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV

Method of inducing dedifferentiation of somatic cells with small molecules to prepare rejuvenated mesenchymal stem cells and uses thereof

A preparation method and applications of rejuvenated and regenerative fibroblasts, where the rejuvenated and regenerative fibroblasts are prepared from normal fibroblasts by inhibiting the JAK-STAT signaling pathway. The rejuvenated and regenerative fibroblasts are prepared by treating the target cells with a small molecular combination, a cytokine combination or a recombinant protein combination. This application further provides an application of the rejuvenated and regenerative fibroblasts in the reprogramming or rejuvenation of cells, tissues, organs and organisms.
Owner:YUNNAN JICI INSITUTE FOR REGENERATIVE MEDICINE CO LTD

Method for rejuvenating cells by reprogramming in non-phase separation transcription factor mediated initiation stage

The invention provides a method for rejuvenating cells by reprogramming in a phase-free separation transcription factor mediated initiation stage. Through improvement of phase-free separation of transcription factors, a recombinant vector is constructed and introduced into a target cell, and the cell is controlled in a reprogramming starting stage, so that the technical effect of rejuvenation is achieved.
Owner:SHENZHEN GENTURN LIFE CO LTD

Methods and products for transfecting cells

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
Owner:FACTOR BIOSCIENCE INC

Overexpressed YTHDC2 macrophage and pharmaceutical application thereof

The invention discloses an overexpression YTHDC2 macrophage and a pharmaceutical application of the overexpression YTHDC2 macrophage. The overexpressed YTHDC2 macrophage disclosed by the invention is obtained by modifying and reprogramming a YTHDC2 gene. The medicine application comprises an application of the overexpressed YTHDC2 macrophage in preparation of a medicine for killing breast cancer cells; the invention relates to application of overexpressed YTHDC2 macrophages in preparation of breast cancer cell targeting drugs. The invention relates to application of overexpressed YTHDC2 macrophages as a drug carrier for targeting breast cancer cells. Compared with the prior art, the expression quantity of the YTHDC2 gene of the overexpressed YTHDC2 macrophage is 5 times higher than that of the common macrophage, and the overexpressed YTHDC2 macrophage shows an M1 type anti-tumor phenotype. The obvious effects of targeting and killing breast cancer cells are realized.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Method for obtaining expansible pluripotent stem cells from peripheral blood mononuclear cells through reprogramming

The invention discloses a method for obtaining expansible pluripotent stem cells from peripheral blood mononuclear cells through reprogramming, and relates to the technical field of biology. The method for obtaining the expansible pluripotent stem cells from the peripheral blood mononuclear cells through reprogramming comprises the following steps that the peripheral blood mononuclear cells (PBMC) are subjected to three stages of reprogramming to obtain the expansible pluripotent stem cells (EPSC); the reprogramming of the three stages comprises the following specific steps: S1, a peripheral blood mononuclear cell amplification stage; s2, a plasmid electroporation stage; s3, an induction stage of an LCDM-containing four-factor culture medium; according to the method, the PBMC cells are directly subjected to reprogramming operation in a plasmid electrotransfection manner, so that EPSC cloning is obtained, the reprogramming period is shortened, and the efficiency is improved; according to the reprogramming method, the time for obtaining the expansible pluripotent stem cells is obviously shortened, the induction efficiency is higher, the operation is simple, no viral vector is introduced, and the reprogramming method has a good application prospect.
Owner:SHENZHEN BEIKEYUAN CELL TECH CO LTD +1

Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods

The present disclosure is directed to a method of generating a population of neurons. This method involves providing a population of human glial progenitor cells: providing a recombinant genetic construct comprising (i) a promoter and / or enhancer for a gene which is selectively or specifically expressed by human glial progenitor cells, and (ii) a nucleic acid sequence encoding one or more neuronal reprogramming factors for producing neurons from glial progenitor cells, where the nucleic acid sequence is operably linked to the 3′ end of said promoter and / or enhancer to achieve expression of the one or more neuronal reprogramming factors; transfecting cells of the glial progenitor cell population with the recombinant genetic construct; and culturing the population after said transfecting under conditions suitable for neuron production from the transfected glial progenitor cells of the population. Also disclosed are methods of inducing the production of neurons, as well as recombinant genetic constructs.
Owner:UNIVERSITY OF ROCHESTER

Preparation method and application of bacterial biomimetic vesicles for reprogramming macrophages

The present invention discloses a preparation method and application of a bacterial bionic vesicle for reprogramming macrophages. The preparation of the bacterial bionic vesicle is to first fuse the bacterial outer membrane anchor protein with the IFN-γ gene, and then use high-pressure homogenization technology to drive genetically engineered bacteria to extrude from the cracks and self-assemble into bacterial bionic vesicles modified with IFN-γ surface. In vitro, the bacterial bionic vesicles of the present invention can promote the reprogramming of M1 macrophages into M2 macrophages, and release nitric oxide to directly kill tumor cells. In vivo, the bacterial bionic vesicles can efficiently enrich in the tumor area by virtue of their nanosize, reprogram the tumor-promoting M2TAMs to the tumor-killing M1TAMs and coordinate adaptive immunity to jointly inhibit tumor growth. In short, the bacterial bionic vesicles of reprogramming macrophages of the present invention are a powerful immunomodulator, which significantly inhibits tumor growth in a variety of tumor models and is of great significance in the immunotherapy of tumors.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Reprogrammable iscb nucleases and uses thereof

Systems, methods and compositions for targeting polynucleotides are detailed herein. In particular, engineered DNA-targeting systems comprising IscB polypeptides, novel IscB nucleases and reprogrammable targeting nucleic acid components and methods and application of use are rovided.
Owner:THE BROAD INST INC +1